Hyaluronan-mediated motility receptor (RHAMM) immunohistochemical expression and androgen deprivation in normal peritumoral, hyperplasic and neoplastic prostate tissue

BJU International

Volumn 113, Issue 5, 2014, Pages 822-829

  Korkes, Fernando ^d   De Castro, Marilia Germanos ^a   De Cassio Zequi, Stenio ^b   Nardi, Lívia ^c   Del Giglio, Auro ^d   De Lima Pompeo, Antonio Carlos ^d  

^a FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

^c Genos Laboratory   (Brazil)

^d FACULDADE DE MEDICINA DO ABC   (Brazil)

Author keywords

androgen receptor; cyproterone; hormonal resistance; hyaluronan mediated motility receptor; hyaluronic acid; prostatic neoplasms; RHAMM; testosterone antagonists and inhibitors

Indexed keywords

CYPROTERONE ACETATE; FINASTERIDE; HYALURONAN MEDIATED MOTILITY RECEPTOR; RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER TISSUE; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TISSUE LEVEL; TRANSURETHRAL RESECTION; TREATMENT DURATION;

ANDROGEN RECEPTOR; CYPROTERONE; HORMONAL RESISTANCE; HYALURONAN-MEDIATED MOTILITY RECEPTOR; HYALURONIC ACID; PROSTATIC NEOPLASMS; RHAMM; TESTOSTERONE/ANTAGONISTS AND INHIBITORS;

AGED; ANDROGEN ANTAGONISTS; ANTIGENS, CD44; DISEASE PROGRESSION; EXTRACELLULAR MATRIX PROTEINS; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; PROGNOSIS; PROSTATE; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84898861399     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12339     Document Type: Article

References (32)

1. Gittes RF,. Carcinoma of the prostate. N Engl J Med 1991; 324: 236-245
2. Scher HI, Steineck G, Kelly WK,. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 1995; 46: 142-148
3. Huggins C, Hodges CV,. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002; 167: 948-952
4. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59: 572-583
5. Hu R, Dunn TA, Wei S, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009; 69: 16-22
6. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T,. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001; 61: 3550-3555 (Pubitemid 32694958)
7. Aaltomaa S, Lipponen P, Tammi R, et al. Strong stromal hyaluronan expression is associated with PSA recurrence in local prostate cancer. Urol Int 2002; 69: 266-272 (Pubitemid 35365379)
8. Kobayashi N, Miyoshi S, Mikami T, et al. Hyaluronan deficiency in tumor stroma impairs macrophage trafficking and tumor neovascularization. Cancer Res 2010; 70: 7073-7083
9. Naor D, Sionov RV, Ish-Shalom D,. CD44: structure, function, and association with the malignant process. Adv Cancer Res 1997; 71: 241-319 (Pubitemid 27197761)
10. Turley EA, Naor D,. RHAMM and CD44 peptides-analytic tools and potential drugs. Front Biosci (Landmark Ed) 2012; 17: 1775-1794
11. Turley EA, Austen L, Moore D, Hoare K,. Ras-transformed cells express both CD44 and RHAMM hyaluronan receptors: only RHAMM is essential for hyaluronan-promoted locomotion. Exp Cell Res 1993; 207: 277-282 (Pubitemid 23246799)
12. Greiner J, Li L, Ringhoffer M, et al. Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia. Blood 2005; 106: 938-945 (Pubitemid 41076438)
13. Mohapatra S, Yang X, Wright JA, Turley EA, Greenberg AH,. Soluble hyaluronan receptor RHAMM induces mitotic arrest by suppressing Cdc2 and cyclin B1 expression. J Exp Med 1996; 183: 1663-1668 (Pubitemid 26134308)
14. Greiner J, Schmitt A, Giannopoulos K, et al. High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica 2010; 95: 1191-1197
15. Gust KM, Hofer MD, Perner SR, et al. RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. Neoplasia 2009; 11: 956-963
16. Hamilton SR, Fard SF, Paiwand FF, et al. The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J Biol Chem 2007; 282: 16667-16680 (Pubitemid 47100370)
17. Lin SL, Chang D, Chiang A, Ying SY,. Androgen receptor regulates CD168 expression and signaling in prostate cancer. Carcinogenesis 2008; 29: 282-290 (Pubitemid 351359666)
18. Lin SL, Chang D, Ying SY,. Hyaluronan stimulates transformation of androgen-independent prostate cancer. Carcinogenesis 2007; 28: 310-320 (Pubitemid 46321846)
19. Menon S, Gujral S, Bakshi G, Tongaonkar HB,. Bilateral testicular metastasis from prostatic adenocarcinoma mimicking an intertubular pattern of seminoma and expressing Rhamm. J Cancer Res Ther 2010; 6: 97-99
20. Spans L, Atak ZK, Van Nieuwerburgh F, et al. Variations in the exome of the LNCaP prostate cancer cell line. Prostate 2012; 72: 1317-1327
21. Klotz LH, Goldenberg SL, Jewett M, et al. CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group. Urology 1999; 53: 757-763 (Pubitemid 29163041)
22. D'Amico AV, Whittington R, Malkowicz SB, et al. Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology 2000; 55: 572-577 (Pubitemid 30157966)
23. Itano N, Zhuo L, Kimata K,. Impact of the hyaluronan-rich tumor microenvironment on cancer initiation and progression. Cancer Sci 2008; 99: 1720-1725
24. Maxwell CA, McCarthy J, Turley E,. Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions? J Cell Sci 2008; 121: 925-932 (Pubitemid 351639411)
25. Toole BP, Slomiany MG,. Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin Cancer Biol 2008; 18: 244-250
26. Toole BP,. Hyaluronan-CD44 Interactions in Cancer: paradoxes and Possibilities. Clin Cancer Res 2009; 15: 7462-7468
27. Lipponen P, Aaltomaa S, Tammi R, Tammi M, Agren U, Kosma VM,. High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer. Eur J Cancer 2001; 37: 849-856 (Pubitemid 32323962)
28. Turley EA, Noble PW, Bourguignon LY,. Signaling properties of hyaluronan receptors. J Biol Chem 2002; 277: 4589-4592 (Pubitemid 34968484)
29. Eckel-Passow JE, Lohse CM, Sheinin Y, Crispen PL, Krco CJ, Kwon ED,. Tissue microarrays: one size does not fit all. Diagn Pathol 2010; 5: 48
30. Bertheau P, Cazals-Hatem D, Meignin V, et al. Variability of immunohistochemical reactivity on stored paraffin slides. J Clin Pathol 1998; 51: 370-374 (Pubitemid 28289123)
31. Bullock MJ, Srigley JR, Klotz LH, Goldenberg SL,. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial. Am J Surg Pathol 2002; 26: 1400-1413 (Pubitemid 35239416)
32. Korkes F, Gasperini R, Korkes KL, Silva Neto DC, Castro MG,. Testicular metastases: a poor prognostic factor in patients with advanced prostate cancer. World J Urol 2009; 27: 113-115